Abstract: The present invention relates to carbazoles/fluorenes, to processes for their preparation and to their use for preparing pharmaceutical agents for the treatment of disorders connected to the EP2 receptor.

Abstract: The present patent application relates to acyltryptophanols of the general formula I, in which Q, X, Y, W, R1, R2, R3, R4, R5, R8 have the meanings stated in the description. The compounds according to the invention are effective FSH antagonists and can be used for example for fertility control in men or in women, or for the prevention and/or treatment of osteoporosis.

Abstract: A method for in vitro screening a group of test substances for a ligand using two assay systems, i.e. a cellular or tissue assay system and an enzymatic assay system, is described. First, those test substances are selected which have transcriptional ER-mediated activity measured by an ER-driven reporter gene in the cellular or tissue assay system with an EC50(ER)(half-maximally effective ligand concentration) lower than or equal to 10 nmol/l. Then in an enzymatic assay system the selected test substances having the required transcriptional ER-mediated activity are tested by measuring a physical-chemical interaction (recruitment) of SRC-1 and the ER in the presence of the test substances. The selected ligand activates the ER and induces interaction with the co-present SRC-1 with an E50(ER+SRC) higher than or equal to 100 nmol/l.

Abstract: The invention relates to novel vitamin D derivatives of general formula (I), a method for the production thereof, intermediate products of the method and the utilization of vitamin D derivatives for producing medicaments.

Abstract: The invention relates to new vitamin D derivatives of general formula (I), process for their production, intermediate products of the process as well as the use for production of pharmaceutical agents.

Abstract: A method of an in vitro screening for a ligand using two assay systems i.e. in a first cellular or tissue assay system, selecting the ligand with transcriptional ER-mediated activity measured by an ER-driven reporter gene, whereby in the first assay system the ligand activates the potency with an EC50(ER) (half-maximally effective ligand concentration) lower than to 10 nmol/l, and, in a second enzymatic assay system, selecting the physical-chemical interaction (recruitment) of SRC-1, wherein the ligand activates the ER and induces interaction with the co-present SRC-1 with an EC50(ER+SRC) higher than to 100 nmol/l.

Abstract: Described are new vitamin D derivatives such as of the formula (I) detailed in this disclosure. Also described are methods for preparing these derivatives, inter mediates used to prepare the derivatives and use of the derivatives as pharmaceutical agents.

Abstract: The invention relates to new vitamin D derivatives of general formula (I), process for their production, intermediate products of the process as well as the use for production of pharmaceutical agents.

Abstract: The present invention relates to novel thrombolitic v-PA's which dissolve blood clots in the human body and thus are suitable for the treatment of cardial infarction, for example.